Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1999

01-08-1999 | ORIGINAL ARTICLE

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide

Authors: Antje May-Manke, Heyo Kroemer, Georg Hempel, Frank Bohnenstengel, Barbara Hohenlöchter, Gottfried Blaschke, Joachim Boos

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1999

Login to get access
Metadata
Title
Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide
Authors
Antje May-Manke
Heyo Kroemer
Georg Hempel
Frank Bohnenstengel
Barbara Hohenlöchter
Gottfried Blaschke
Joachim Boos
Publication date
01-08-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050985

Other articles of this Issue 4/1999

Cancer Chemotherapy and Pharmacology 4/1999 Go to the issue

ORIGINAL ARTICLE

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin

ORIGINAL ARTICLE

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer

ORIGINAL ARTICLE

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

ORIGINAL ARTICLE

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

ORIGINAL ARTICLE

Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIα and β

ORIGINAL ARTICLE

Acquired resistance to O 6-benzylguanine plus chloroethylnitrosoureas in human breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits